VolitionRx Files Patent for Ebola Test

VolitionRx has filed a patent for an Ebola triage test using Nu.Q technology. This test is intended to help diagnose and manage Ebola cases. The use of Nu.Q technology is a key aspect of the test. VolitionRx's development of this test is a significant step forward in Ebola diagnosis. The patent filing is an important step in bringing the test to market. The test has the potential to improve Ebola diagnosis and treatment outcomes. Further details about the test and its applications are expected to emerge. The impact of this test on Ebola management could be substantial.